Cefotaxime
Based on 14 publication(s) in Google Scholar
Cefotaxime, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.74%
- CAS No.: 63527-52-6
- Formule: C16H17N5O7S2
- Masse moléculaire:455.47
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Pediatric Drug Library
HY-L104
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Chinese Baijiu Compound Library
HY-L241
Publications Citing Use of MedChemExpress (MCE) Cefotaxime
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Cell. 2025 Mar 6;188(5):1330-1348.e27. [Abstract]
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Biomolecules. 2026 Apr 17;16(4):598. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- Int J Antimicrob Agents. 2025 Jun 9:107551. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- J Antibiot (Tokyo). 2025 Mar;78(4):265-273. [Abstract]
- Chin J Traumatol. 2024 Jul 3:S1008-1275(24)00075-0. [Abstract]
- Biomed Chromatogr. 2024 Jul 8:e5955. [Abstract]
- bioRxiv. 2024 May 10.
Customer Validation & Images
-
Microbiological Assay
Voir tous les produits spécifiques à Isoform Beta-lactamase
MoreVoir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
|
β-lactam |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| S2 | IC50 |
800 μM
Compound: Cefotaxime
|
TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells
TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells
|
[PMID: 12005172] |
| S2 | IC50 |
>2000 μM
Compound: Cefotaxime
|
TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells
TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells
|
[PMID: 12005172] |
Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female, specific pathogen free, 8-week-old BALB/c mice[4].
-
Dosage:30 mg/kg.
-
Administration:IP every 6 h.
-
Result:The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each).
Chemical Information
-
CAS No. 63527-52-6
-
Appearance Solid
-
Masse moléculaire 455.47
-
Formule C16H17N5O7S2
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(COC(C)=O)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O
-
Synonyms
Cefotaxim; HR-756
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Cell
2025 Mar 6;188(5):1330-1348.e27. PMID: 39855200 -
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Biomolecules
The Effects of Baicalin in Combination with Cefotaxime on the Biofilm and Metabolic Reprogramming of Multidrug-Resistant Pseudomonas aeruginosa. [Abstract]2026 Apr 17;16(4):598. PMID: 42072719 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Jun 9:107551. PMID: 40499596 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732
Cefotaxime purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]
Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.
-
-
J Antibiot (Tokyo)
In vitro assessment of the synergistic effects of cefotaxime, colistin, and fosfomycin combinations against foodborne resistant Escherichia coli and Salmonella isolates. [Abstract]2025 Mar;78(4):265-273. PMID: 39910346 -
Chin J Traumatol
The cytochrome P4501A1 (CYP1A1) inhibitor bergamottin enhances host tolerance to multidrug-resistant Vibrio vulnificus infection. [Abstract]2024 Jul 3:S1008-1275(24)00075-0. PMID: 38981821 -
Biomed Chromatogr
An analytical method using salting-out assisted liquid-liquid extraction to quantify ceftriaxone from micro volumes of human serum. [Abstract]2024 Jul 8:e5955. PMID: 38973552 -
Solvant et solubilité
DMSO : 250 mg/mL (548.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 100 mg/mL (219.55 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hee-Chang Jang, et al. In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis. PLoS One. 2014 Jun 30;9(6):e101118. [Content Brief]
[2]. Woodfield JC, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9. [Content Brief]
[3]. Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7. [Content Brief]
[4]. Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9. [Content Brief]
[5]. E L Francke, et al. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. Am J Med. 1981 Sep;71(3):435-42. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.1955 mL | 10.9777 mL | 21.9553 mL | 54.8884 mL |
| 5 mM | 0.4391 mL | 2.1955 mL | 4.3911 mL | 10.9777 mL | |
| 10 mM | 0.2196 mL | 1.0978 mL | 2.1955 mL | 5.4888 mL | |
| 15 mM | 0.1464 mL | 0.7318 mL | 1.4637 mL | 3.6592 mL | |
| 20 mM | 0.1098 mL | 0.5489 mL | 1.0978 mL | 2.7444 mL | |
| 25 mM | 0.0878 mL | 0.4391 mL | 0.8782 mL | 2.1955 mL | |
| 30 mM | 0.0732 mL | 0.3659 mL | 0.7318 mL | 1.8296 mL | |
| 40 mM | 0.0549 mL | 0.2744 mL | 0.5489 mL | 1.3722 mL | |
| 50 mM | 0.0439 mL | 0.2196 mL | 0.4391 mL | 1.0978 mL | |
| 60 mM | 0.0366 mL | 0.1830 mL | 0.3659 mL | 0.9148 mL | |
| 80 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.6861 mL | |
| 100 mM | 0.0220 mL | 0.1098 mL | 0.2196 mL | 0.5489 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cefotaxime Related Classifications
HY-A0088A Related Classifications
Powered by Bioz